NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
DualityBio Inc.
Tanabe Pharma America, Inc.
CRISPR Therapeutics
Marengo Therapeutics, Inc.
Numab Therapeutics AG
University of Alabama at Birmingham
Cancer Research UK
Elucida Oncology
Evopoint Biosciences Inc.
Centre Leon Berard
Kineta Inc.
Genelux Corporation
Radboud University Medical Center